- About UsOpenClose
- LeadershipOpenClose
- BoardOpenClose
- TechnologyOpenClose
- PublicationsOpenClose
- PipelineOpenClose
- For PatientsOpenClose
- For InvestorsOpenClose
- NewsroomOpenClose
- Media CoverageOpenClose
- Press ReleasesOpenClose
Our leadership team is well-positioned to deliver on the promise of engineered macrophages as a transformative approach to the treatment of cancer.
With decades of experience to lean upon, working in concert with a team of passionate scientists, our goal is to develop the next generation of cell therapies to change the lives of cancer patients.
Steven Kelly joined Carisma in February 2018 bringing nearly thirty years of experience in Pharma/Biotech at all phases of the business across multiple therapeutic categories. Prior to joining Carisma, Mr. Kelly held a number of leadership positions in the biotechnology industry including: CEO, Pinteon Therapeutics; CEO, Theracrine; CCO, BioVex; CEO, Innovive Pharmaceuticals; as well as various commercial and manufacturing roles at Sanofi, IDEC Pharmaceuticals and Amgen.
Steve holds a BS from the University of Oregon and an MBA from Cornell University.
Mike is a co-inventor of the CAR-Macrophage technology and a scientific co-founder of Carisma. In his role as Chief Scientific Officer, he oversees the research & discovery efforts of the company.
Mike developed CAR-Macrophages during his doctoral thesis under the co-mentorship of Saar Gill and Carl June at the University of Pennsylvania. Michael’s scientific expertise is in the intersection of immunology, synthetic biology, cancer immunotherapy, and translational pharmacology.
Mike previously earned a Doctor of Pharmacy degree from the University of Sciences in Philadelphia, and a PhD in Pharmacology from the University of Pennsylvania.